Neogenomics, Inc.
Could not find a ticker for this position, may be a filing error
A laboratory that focuses exclusively on cancer testing, helping oncologists and pathologists diagnose tumors and choose treatments through genetic and molecular analysis. Founded in 2001 in Fort Myers, Florida, by a pathologist and a healthcare executive, it has grown into one of the largest oncology-focused reference labs in the United States. The name blends "neo" — Greek for "new" — with "genomics," a nod to the modern genetic techniques at its core.
0.25% Convertible Senior Notes due 2028
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Mathew P. Arens | 13G/APassive | 8.37% | 10.76M | Aug 14, 2026 |
| First Light Asset Management, LLC | 13G/APassive | 7.99% | 10.26M | Aug 14, 2026 |
| BlackRock, Inc. | 13G/APassive | 15.6% | 20.36M | Jul 30, 2026 |
| First Trust Portfolios L.P. | 13GPassive | 7.77% | 10.11M | Jul 30, 2026 |
| First Trust Advisors L.P. | 13GPassive | 7.77% | 10.11M | Jul 30, 2026 |
| The Charger Corporation | 13GPassive | 7.77% | 10.11M | Jul 30, 2026 |
| Greenhouse Funds LLLP | 13G/APassive | 7.1% | 9.22M | May 15, 2026 |
| Greenhouse GP LLC | 13G/APassive | 7.1% | 9.22M | May 15, 2026 |
| Joseph Milano | 13G/APassive | 7.1% | 9.22M | May 15, 2026 |
| Millennium Management LLC | 13G/APassive | 1.7% | 2.22M | May 13, 2026 |